Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.

Retrovirology - 9 Jan 2007

Heaslet Holly, Lin Ying-Chuan, Tam Karen, Torbett Bruce E, Elder John H, Stout C David

Abstract excerpt

We have obtained the 1.7 A crystal structure of FIV protease (PR) in which 12 critical residues around the active site have been substituted with the structurally equivalent residues of HIV PR (12X FIV PR). The chimeric PR was crystallized in complex with the broad-based inhibitor TL-3, which inhibits wild type FIV and HIV PRs, as well as 12X FIV PR and several drug-resistant HIV mutants 1234. Biochemical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aspartic Acid Endopeptidases
Share to Cats
Share to Crystallization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Crystallography, X-Ray

Share to Dimerization

Share to HIV Protease

Share to Immunodeficiency Virus, Feline

Share to Protease Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 17212810
DOI: 10.1186/1742-4690-4-1
PMCID: PMC1781954

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.PMID 17212810Read ↗

Structural characterization of B and non-B subtypes of HIV-protease: insights into the natural susceptibility to drug resistance development.Semantic proximity Read ↗

Flap-site Fragment Restores Back Wild-type Behaviour in Resistant Form of HIV Protease.Semantic proximity Read ↗

Comparative studies on inhibitors of HIV protease: a target for drug design.Semantic proximity Read ↗

An allosteric modulator of HIV-1 protease shows equipotent inhibition of wild-type and drug-resistant proteases.Semantic proximity Read ↗

Response of feline immunodeficiency virus (FIV) to tipranavir may provide new clues for development of broad-based inhibitors of retroviral proteases acting on drug-resistant HIV-1.Semantic proximity Read ↗

Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand.Semantic proximity Read ↗

Pharmacophore‐Based Discovery of Small‐Molecule Inhibitors of Protein–Protein Interactions between HIV‐1 Integrase and Cellular Cofactor LEDGF/p75Semantic proximity Read ↗

High resolution structures of HIV-1 RT from four RT–inhibitor complexesSemantic proximity Read ↗

Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate.Semantic proximity Read ↗

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.Semantic proximity Read ↗

Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.Semantic proximity Read ↗

Structure-Activity Relationships of HIV-1 Integrase Inhibitors - Enzyme- Ligand InteractionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.